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Plasma soluble thrombomodulin and soluble endothelial protein C receptor
levels in colorectal cancer patients
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Aim: Thrombomodulin (TM) and endothelial protein C receptor (EPCR) are 2 transmembrane proteins that are thought to play an
important role in cancer. We aimed to discover whether these 2 proteins are prognostic indicators in colorectal cancer.
Materials and methods: Plasma TM and EPCR levels were measured using the ELISA method in 50 patients in different tumor stages
that had been recently diagnosed with colorectal cancer and in a healthy control group of 50 people.
Results: In colorectal cancer patients, higher plasma TM (21.3 ± 22.8 ng/mL, 13.2 ± 16.2 ng/mL, P = 0.010) and plasma EPCR levels
(149.9 ± 79.6, 113.3 ± 49.3, P = 0.007) were determined compared to the control group. No statistically significant relationship was
present between plasma TM, EPCR levels and tumor stage, tumor localization, tumor differentiation, lymphovascular invasion state,
microvascular thrombus existence, and thrombosis progression (P > 0.05).
Conclusion: We think that these 2 proteins are released into plasma as an indicator of endothelial dysfunction and can play a role in
pathogenesis and biology of colorectal cancer.
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1. Introduction
Colorectal cancer is one of the most frequently diagnosed
cancers in the world, and the biology of colorectal cancer
is now known better because of ongoing studies. However,
there is still much work to be done in defining new
prognostic factors and guiding treatment decisions.
With recent studies, it is suggested that hemostatic
system components play an important role in cancer
progression. Thrombin and fibrin, which are the last
products of the coagulation cascade, contribute to
proliferation, migration, local invasion, angiogenesis, and
metastatic spread of cancer cells (1,2).
Thrombin plays a key role in the operation of
coagulation and anticoagulant systems. The most
important components of the protein C pathway, which
is classically known as the anticoagulant system, are
thrombomodulin (TM) and endothelial protein C
receptor (EPCR). TM activates protein C by forming a
complex with thrombin. With the binding of protein C
to in vivo EPCR, this activation increases 20 times more.
When the activated protein C (APC) separates from
* Correspondence: cebilir@yahoo.com
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EPCR, it binds to an appropriate surface on protein S and
together they decrease uncontrolled thrombosis formation
by inactivating factor Va and factor VIIIa (3,4). The role
of these 2 proteins’ expression in tissues and the role of
their soluble forms regarding malignancy are still not
completely known. However, studies have shown that
soluble TM increases in various cancer types (colorectal,
pancreas, breast, leukemia) and plasma level increases
further with progression of the disease (5). Although
expression of EPCR in different tumor cell series is shown,
there is no information about its role in malignancy, even
though increased levels of its soluble form can be related
with elevated thrombosis risk (6,7).
The aim of our study was to measure plasma-soluble
TM and EPCR levels in colorectal cancer patients, and then
compare these results with both a healthy control group and
within the patient group stratified according to stage and
metastatic status at the time of diagnosis. Additionally, the
relation of soluble TM (sTM) and soluble EPCR (sEPCR)
with tumor differentiation, lymphovascular invasion state,
and microvascular thrombus existence was studied.
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2. Materials and methods
Fifty patients who applied to the Karaelmas (now Bülent
Ecevit) University Training and Research Hospital
Medical Oncology Outpatient Clinic between January
2010 and December 2010, and who had recently been
diagnosed with colorectal cancer and had not received any
chemotherapy and radiotherapy, were enrolled in the study.
The control group contained 50 sex- and age-matched
healthy individuals free of inflammatory, neoplastic,
atherosclerotic, or connective tissue diseases, who were
recruited from hospital staff and patients who had come in
for check-ups. Informed consent was obtained from every
patient and control group member before enrollment. The
study was approved by the Ethical Committee for Scientific
Studies at Karaelmas University, Zonguldak, Turkey.
The following patients were not accepted into the study:
those who received preoperative chemo/radiotherapy;
those with systemic diseases such as renal insufficiency,
chronic liver disease, and diabetes mellitus; those with
cerebral infarct and multiple sclerosis history; those with
sepsis and disseminated intravascular coagulation; those
with a history of venous thromboembolism and coronary
events; and those who were active smokers.
Five of the 50 patients who participated in the study
were in the advanced stage (inoperable). Postoperative
pathology records of the remaining 45 patients
were reviewed and tumor differentiation (grade),
lymphovascular invasion state, and microvascular
thrombus existence were recorded. Lymphovascular
invasion state and microvascular thrombus existence were
determined with hematoxylin and eosin staining.
The seventh edition (2010) of the TNM classification
system was used to stage patients. Staging was done by
taking into account clinical, preoperative, radiological,
intraoperative, and postoperative pathological findings.
The patients were followed in respect to thromboembolic
events and general survival period as of their entry date
into the study until 1 June 2010, when the study ended.
From each participant (patients and controls), 5 mL of
blood was taken for the study of plasma sEPCR and sTM
levels, and the plasmas obtained after centrifuge were kept
at –80 °C until the measurements were carried out.

Plasma sEPCR and sTM levels were studied in the
Zonguldak Karaelmas University Medical Faculty Hospital
Immunology Laboratory. sEPCR and sTM concentrations
from plasma samples were studied in microplate well and
SIRIOS devices by Asserachrom EPCR and Asserachrom
TM kits (Diagnostica Stago, France) with the enzymelinked immunosorbent assay (ELISA) method.
2.1. Statistical analyses
Statistical evaluations were done using SPSS 13.0.
Descriptive statistics were expressed as mean ± standard
deviation for numeric data and as number and percent
for categorical data. For categorical variants, the relations
between intergroup differences and variants were tested
using the chi-square test. The significance test of the
difference between 2 means was used for the comparison
of 2 groups in respect to numeric variants, which shows
normal distribution. The Mann–Whitney U test was used
for numeric variants that did not show normal distribution.
The difference between TM and EPCR levels according to
stages was tested with Kruskal–Wallis variance analysis.
Results were evaluated to be within the confidence interval
of 95%, and P < 0.05 was accepted as significant.
3. Results
The median follow-up period was 11.5 (2–17) months.
In both groups, there were 25 female (50%) and 25 male
(50%) cases. The mean age of the patients was 60.8 ± 11.7
years and the mean age of the control group was 57.6 ± 6.4.
No significant difference in respect to age and sex between
control and patient groups was seen. In the patient group,
the median general survival period was 11.5 (2–17)
months, and the general survival rate was 78% during the
follow-up period. The death rate was 22%.
Plasma sTM and sEPCR levels in the control group
and the colorectal cancer group are shown in Table 1. The
plasma sTM levels in colorectal cancer patients were found
to be significantly higher than in the control group (21.3
± 22.8 ng/mL, 13.2 ± 16.2 ng/mL, P = 0.010). In addition,
plasma sEPCR levels in colorectal cancer patients were
found to be significantly higher than in the control group
(149.9 ± 79.6, 113.3 ± 49.3, P = 0.007). There was no
significant difference between the groups for sTM and
sEPCR according to sex (Table 2).

Table 1. Average plasma sTM and sEPCR levels in colorectal cancer patients and control groups.
Patient
n = 50

Control
n = 50

P

sTM (ng/mL)

21.3 ± 22.8

13.2 ± 16.2

0.010

sEPCR (ng/mL)

149.9 ± 79.6

113.3 ± 49.3

0.007
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Table 2. Average plasma sTM and sEPCR levels in patient and control group according to sex.
Patient

Control

Female
n = 25

Male
n = 25

P

Female
n = 25

Male
n = 25

P

sTM (ng/mL)

19.0 ± 18.8

23.6 ± 26.4

0.477

12.7 ± 15.5

13.7 ± 17.1

0.398

sEPCR (ng/mL)

136.5 ± 75.7

163.3 ± 82.7

0.239

104.1 ± 39.9

122.5 ± 56.5

0.190

According to the tumor localization, metastases,
lymphovascular invasion, microvascular thrombus,
tumor grade, and tumor stage, there were no statistically
significant differences for plasma sTM and plasma sEPCR
levels between the patient group and control group (Table
3).

From the beginning of the study to 1 June 2010, when
the study ended, the patients were followed up with for
thromboembolic events, both in polyclinic examinations
and at home via telephone. No thromboembolic event (deep
vein thrombosis, pulmonary embolism, cerebral embolism,
etc.) occurred in any patient within the follow-up period

Table 3. Average plasma sTM and sEPCR levels in patient and control group according to pathology.

Colon
n = 35

Rectum
n = 15

P

sTM (ng/mL)

23.6 ± 25.6

16.1 ± 13.8

0.296

sEPCR (ng/mL)

156.3 ± 76.0

135.0 ± 88.3

0.391

With metastasis
n = 12

Without metastasis
n = 38

P

sTM (ng/mL)

20.0 ± 15.0

21.7 ± 24.9

0.496

sEPCR (ng/mL)

131.5 ± 63.8

155.7 ± 83.9

0.496

Grade 1
n = 14

Grade 2–3
n = 31

P

sTM (ng/mL)

27.1 ± 31.5

19.2 ± 19.2

0.304

sEPCR (ng/mL)

165.0 ± 86.2

150.7 ± 78.4

0.584

Microvascular thrombus (+)
n=6

Microvascular thrombus
(–) n = 39

P

sTM (ng/mL)

27.9 ± 25.0

20.7 ± 23.6

0.676

sEPCR (ng/mL)

199.9 ± 94.6

148.3 ± 76.8

0.144

Stage 1
n=4

Stage 2
n = 20

Stage 3
n = 14

Stage 4
n = 12

P

sTM (ng/mL)

17.0 ± 16.6

28.7 ± 31.2

13.1 ± 10.8

20.0 ± 15.0

0.514

sEPCR(ng/mL)

108.7 ± 32.1

168.2 ± 81.8

151.3 ± 95.2

131.5 ± 63.8

0.364
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4. Discussion
TM is mainly a transmembrane glycoprotein expressed in
microvascular endothelium. It has 3 important functions:
coagulation, inflammation, and cell adhesion. The role
of TM in malignancy is still not completely known. It
may affect tumor growth and metastasis with its natural
anticoagulant function (8). Since TM expression is
shown in many different tumors including breast cancer,
esophageal squamous cell cancer, lung cancer, melanoma,
and ovary cancer, it is thought that this protein can play
a role in the control of tumor growth and metastasis (9–
14). TM expression tends to be lower in metastatic lesions
compared to primary samples. In tumors, the decreased
TM can induce differentiation loss and can improve
metastatic character. In vitro studies showed that TM
decreases tumor cell proliferation and invasion (15,16).
EPCR binds to protein C, and thereby increases the
activation of protein C by the thrombin–TM complex
(17). Under normal conditions, there is sEPCR in plasma
in a measurable quantity. Although the physiologic
importance of sEPCR is not known, it is known to increase
in inflammatory conditions such as sepsis and lupus (18).
It is known that EPCR is expressed from a few cell series in
different tumors (7); however, there is not any information
about plasma level of EPCR in colorectal cancer.
In the studies carried out up until now, the tissue
expressions of TM and EPCR in colorectal cancer have
been studied, but the soluble levels of these 2 proteins
in plasma have not been studied yet. However, in 1993,
Lindahl et al. measured plasma TM levels with ELISA in
97 patients, including 35 colorectal cancer patients and
patients with different cancer types. It was stated that
plasma TM level increases in cancer patients compared
to the healthy control group; however, this increase was
at different rates according to each cancer type (5). In
our study, both plasma TM and EPCR levels increased in
colorectal cancer patients compared to the healthy control
group, and this result was statistically significant.
Plasma level of TM increases depending on the
endothelial damage seen in different pathological
situations. Therefore, it is accepted as an indicator of
endothelial cell damage (15). Zhou et al. measured plasma
TM levels in cancer patients who received radiotherapy
and stated that there is a positive correlation between
radiation dose and plasma TM levels, and that plasma TM
is a useful marker for early determination of the radiation
damage to the endothelial cells in patients exposed to
radiotherapy (19). Suehiro et al. evaluated TM expression
in patients with hepatocellular carcinoma (HCC), and
they suggested that TM can inhibit adhesion of portal vein
tumor cells due to anticoagulant activity and thereby it can
prevent intrahepatic metastasis (8). When Salmaggi et al.
compared plasma TM levels of patients with glioblastoma

multiforme with a healthy control group, they saw that it
increased significantly (20). As seen in many studies, the
plasma sTM level is higher in cancer patients compared to
healthy individuals.
When we extensively reviewed the studies conducted to
date, we saw that the relation between tumor differentiation,
lymphovascular invasion state, microvascular thrombus
existence in colorectal cancer, and plasma sTM and sEPCR
levels was not studied. In our study, we compared these
variants with plasma sTM and sEPCR levels. We could not
find a statistically significant difference between tumor
differentiation and lymphovascular invasion and plasma
sTM and sEPCR levels.
In the study conducted by Xu et al., plasma TM level
and tissue TM expression were measured in 188 cancer
patients (including lung, pancreas, stomach, colon,
nasopharyngeal, and laryngeal cancer patients), and they
stated that TM expression was low and plasma TM levels
were high in those patients who were metastatic. This
shows that the increase of plasma TM levels in cancer
patients is related to metastasis (21). In addition, low or
no TM expression in cancer cells of lung, oral, and breast
cancer is related to a poor prognosis (8,10,12,14). As is seen,
TM levels can be used as a sensitive indicator to evaluate
the metastasis and progression of cancers. In our study, we
could not find a statistically significant difference when we
compared plasma sTM and sEPCR levels of patients who
were in the advanced stage and had metastasis with those
who were in early stage and did not have metastasis at the
time of diagnosis.
There is limited information about EPCR expression in
cancer tissues. Tsuneyoshi et al. reviewed EPCR expression
in tissue samples with invasive ductal breast carcinoma
and strong EPCR expression was determined. Therefore, it
is suggested that EPCR can play a role in the pathogenesis
and progression of some cancer types (7). In another study,
although the sTM level was higher in chronic liver patients
with HCC compared to chronic liver patients without
HCC, no difference between sEPCR levels in the 2 groups
was found. However, it was shown that high sEPCR level is
related to worse prognosis and death in HCC (22). In some
studies, the effect of the APC/EPCR pathway on tumor
migration and metastasis in melanoma cell series was
reviewed, and it was shown that liver metastasis decreases
50% and lung metastasis decreases 92% in mice showing
EPCR overexpression. With these findings, it is suggested
that the APC/EPCR pathway decreases tumor metastasis
by inhibiting tumor adhesion and migration (23,24). In
our study, EPCR level was determined to be statistically
significantly higher in colorectal cancer patients compared
to the healthy control group. However, no relationship
was found between plasma sEPCR level and disease stage,
metastatic state, tumor differentiation, lymphovascular
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invasion state, and microvascular thrombus existence.
This study is the first to show the increase of plasma sEPCR
level in colorectal cancer patients.
Consequently, these results show that the protein C
pathway, including TM and EPCR, can play roles in the
pathogenesis and biology of colorectal cancer.
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